Going Concern |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Going Concern |
2. Going Concern
The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. As of September 30, 2026, the Company had an unrestricted cash balance of $278 thousand. For the nine months ended September 30, 2026, the Company incurred a net loss of $5.7 million and had a net usage of cash in operating activities of $3.8 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
In April, May and July 2026, the Company received aggregate gross proceeds of approximately $9.5 million from the issuance of the Notes, substantially all of which was used to fund the cash consideration for the Celularity Transaction. We expect the license and acquisition of Celularity, Inc.’s portfolio of commercial-stage regenerative biomaterials will ultimately contribute positive operating cash flows, improve liquidity, and support ongoing operations, although there can be no assurance that it will do so.
On November 10, 2026, the Company entered into and closed Note Amendment and Conversion Agreements with holders of approximately $14.1 million in aggregate principal amount of its convertible notes and a securities purchase agreement for the sale of common stock and warrants, under which it received gross proceeds of approximately $1.2 million, in each case as described in Note 19. The conversion of the amended notes into common stock is conditioned on the completion of the proposed merger described in Note 19, for which no definitive agreement has been entered into. Because the completion of the merger and the conversion of the notes are not within the Company’s control, management has concluded that they do not alleviate the substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management is considering various options to raise capital through equity or debt offerings to fund our current business activities and potential acquisitions. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the condensed consolidated financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.
|